Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 398 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertrophic Clear all

Conditions: Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Interventions: Aficamten, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 24
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Prostatic Hyperplasia, Prostatic Hypertrophy, Benign
Interventions: Doxazosin, Finasteride, Doxazosin placebo, Finasteride placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 50 Years and older · Male only
Enrollment: 3,407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2001
U.S. locations: 17
States / cities: La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 13 more

Conditions: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
Interventions: SGR-1505; Drug
Lead sponsor: Schrödinger, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 16
States / cities: Gilbert, Arizona • Newark, Delaware • Pompano Beach, Florida + 13 more

Conditions: Rheumatoid Arthritis, NOS
Interventions: BMS-582949, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Palm Desert, California • Santa Monica, California • Las Vegas, Nevada + 5 more

Conditions: Cardiomyopathies, Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Restrictive Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy, Left Ventricular Non-compaction Cardiomyopathy
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Hypertrophic
Interventions: embrace device; Device
Lead sponsor: Neodyne Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 13
States / cities: Atherton, California • Bakersfield, California • Danville, California + 10 more

Conditions: Cardiomyopathy, Hypertrophic
Interventions: PET Scan; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Spinal Cord Injuries
Interventions: Low-force muscle stimulation, High-force muscle stimulation, Sequential low-force and high-force muscle stimulation; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Chronic Kidney Disease (CKD) Stage 5, Hypertrophy, Left Ventricular
Interventions: paricalcitol injection 4 mcg/mL, Placebo Injection 4 mcg/mL; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 29
States / cities: Phoenix, Arizona • Tempe, Arizona • Bakersfield, California + 24 more

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cardiomyopathy, Hypertrophic, Cardiomyopathy, Hypertrophic, Familial
Interventions: Perhexiline, Use of bioanalytical assay to monitor plasma levels of perhexiline; Drug · Device
Lead sponsor: Heart Metabolics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: Stanford, California • Indianapolis, Indiana • Baltimore, Maryland + 7 more

Conditions: Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions: Pacritinib, Best Available Therapy; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 50
States / cities: Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 42 more

Conditions: Cardiomyopathy, Hypertrophic
Interventions: Mavacamten; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: West Hollywood, California • Atlanta, Georgia • Boston, Massachusetts + 4 more

Conditions: Hypertrophy, Physical Performance
Interventions: isolate whey protein prior to and immediately after resistance training, isolate whey protein 3 hours prior to and 3 hours after resistance training; Dietary Supplement
Lead sponsor: Marymount University; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Arlington, Virginia

Conditions: Hypertrophic Cardiomyopathy
Interventions: None - this is an observational study; Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2,750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 17
States / cities: New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland + 10 more

Conditions: Hypertrophic Scar
Interventions: Botox; Drug
Lead sponsor: Roy G. Geronemus, M.D.; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Dilated Cardiomyopathy, Hypertrophic Cardiomyopathy, Mitochondrial Cardiomyopathy, Noncompaction Cardiomyopathy, Restrictive Cardiomyopathy
Interventions: Not listed
Lead sponsor: University of California, Irvine; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Irvine, California

Conditions: Acne, Acne Scars - Mixed Atrophic and Hypertrophic, Scars, Wrinkle, Pigment; Lesion, Skin Texture Disorder
Interventions: AVAVA; Device
Lead sponsor: AVAVA, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Hypertension, Left Ventricular Hypertrophy
Interventions: amlodipine/benazepril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 55 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL), De Novo or Transformed Indolent B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, T Cell/Histiocyte-rich Large B-cell Lymphoma, EBV-Positive DLBCL, Nos, Primary Mediastinal [Thymic] Large B-cell Lymphoma (PMBCL), High-Grade B-Cell Lymphoma, Nos, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, Grade 3b Follicular Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma
Interventions: ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy; Drug
Lead sponsor: Patrick C. Johnson, MD; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Gaucher Disease
Interventions: Plant cell expressed recombinant glucocerebrosidase (prGCD); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
U.S. locations: 14
States / cities: La Jolla, California • Aurora, Colorado • Coral Springs, Florida + 11 more

Conditions: Endothelial Dysfunction, Vascular Stiffness, Left Ventricular Hypertrophy, Left Ventricular Dysfunction
Interventions: Sodium Reduction Intervention; Behavioral
Lead sponsor: Tulane University; Other
Eligibility: 40 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Hypertrophic Cardiomyopathy, Left Ventricular Outflow Obstruction, Systolic Anterior Motion
Interventions: SESAME Procedure; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 100 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Boston, Massachusetts + 5 more

Conditions: Benign Prostatic Hypertrophy Requiring Surgical Intervention
Interventions: Lumenis VersaCut Morcellator, Wolf Piranha Morcellator; Device
Lead sponsor: Indiana Kidney Stone Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

Medical Therapy of Prostatic Symptoms

Study of SGR-1505 in Mature B-Cell Neoplasms

PoC in Rheumatoid Arthritis With Methotrexate

Pediatric Cardiomyopathy Mutation Analysis

A Study of a Novel Silicone Dressing to Minimize Scar Formation

The Impact of Exercise-Induced Cardiac Remodeling on Myocardial Efficiency

Novel Intervention to Influence Muscle Plasticity in Veterans

The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5

Genetic Analysis of African-Americans With High Blood Pressure

Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Protein Ingestion Timing on Body Composition and Biochemical Markers in Resistance-trained Males

HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy

Treatment of Hypertrophic Scars With Intradermal Botox

The Genetics of Cardiomyopathy and Heart Failure

AVAVA MIRIA General Use

Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Expanded Access Trial of Plant Expressed Recombinant Glucocerebrosidase (prGCD) in Patients With Gaucher Disease

Sodium Lowering Vascular Effects Trial

NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices

Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures